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Abstract
Emerging phenotypes in long-term survivors with Pompe disease on standard enzyme replacement therapy (ERT) (alglucosidase alfa
20 mg/kg/2 weeks) can include patients with worsening motor function. Whether higher doses of ERT improve skeletal function in these patients
has not been systematically studied. This exploratory, randomized, open-label, 52-week study examined the safety and efficacy of 2 ERT regimens
of alglucosidase alfa (20 mg/kg/week or 40 mg/kg/2 weeks) in 13 patients with Pompe disease and clinical decline or a lack of improvement on
standard ERT: late-onset (n = 4), infantile-onset (n = 9). Cross-reactive immunologic material assay-negative patients were excluded. Eleven of 13
patients completed the study. Trends for improvement were seen in total gross motor function, but not mobility; however, 6 (late-onset, 2;
infantile-onset, 4) of 11 patients (55%) who met the entry criteria of motor decline (late-onset, 4; infantile-onset, 7) showed improvement in motor
and/or mobility skills. No between-regimen differences in efficacy emerged. Two case studies highlight the benefits of increased ERT dose in
patients with Pompe disease experiencing clinical decline. Both alternative regimens were generally well tolerated. This study was limited by the
small sample size, which is not uncommon for small clinical studies of rare diseases. Additionally, the study did not include direct assessment of
muscle pathology, which may have identified potential causes of decreased response to ERT. Results were inconclusive but suggest that increased
ERT dose may be beneficial in some patients with Pompe disease experiencing motor decline. Controlled studies are needed to clarify the benefits
and risks of this strategy.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Keywords: Alglucosidase alfa; Enzyme replacement therapy; Infantile onset; Late onset; Pompe disease; Clinical decline; Dose
1. Introduction
Pompe disease, a rare autosomal recessive neuromuscular
disorder caused by a deficiency of the lysosomal enzyme acid
α-glucosidase (GAA), results in glycogen accumulation in
various organs, primarily muscle tissue [1]. Infantile-onset
Pompe disease represents the most severe form, with early
death due to cardiorespiratory failure within the first year of life
[2]. The main clinical manifestations of Pompe disease include
profound hypotonia/generalized muscle weakness, respiratory
distress, and marked hypertrophic cardiomyopathy [3]. The
only available treatment for Pompe disease, alglucosidase alfa
(Genzyme, a Sanofi company, Cambridge, MA), targets the
underlying cause by replacing the deficient GAA enzyme; and
the recommended dosage is 20 mg/kg/2 weeks [4].
In infants with Pompe disease, alglucosidase alfa treatment
has been shown to extend overall survival and invasive
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ventilation-free survival, reverse cardiomyopathy, and permit
children to achieve gross motor milestones, including
independent walking, not observed in untreated cohorts where
the median age of death was less than 9 months [3,5,6].
However, with increased long-term survival on alglucosidase
alfa, an emerging phenotype characterized by progressive
weakness and decreased motor function has been identified in
patients with infantile-onset Pompe disease that initially
responded well to enzyme replacement therapy (ERT) with
alglucosidase alfa [7,8]. The emergence of this phenotype has
raised the question of whether the currently approved ERT
regimen (alglucosidase alfa 20 mg/kg/2 weeks) eventually may
be insufficient in some patients, even in those who initially
responded well to treatment.
We report on an open-label study (ClinicalTrials.gov,
NCT00483379) including 2 detailed case reports that examine
the efficacy and safety of alternative regimens of alglucosidase
alfa in patients with late-onset and infantile-onset Pompe
disease who experienced clinical decline or a lack of
improvement despite continuation of ERT at the dose
recommended in the package insert of 20 mg/kg/2 weeks.
Together, these results suggest that controlled studies are
warranted to establish the effects of alternative ERT regimens
of alglucosidase alfa in Pompe disease and the development of
new treatment approaches to allow for a continued clinical
benefit.
2. Patients and methods
We first report on an open-label study of 13 cases that
evaluated the safety and efficacy of alternative regimens of
alglucosidase alfa (20 mg/kg/week or 40 mg/kg/2 weeks) in
patients with late-onset or infantile-onset Pompe disease who
experienced clinical decline or lack of improvement while
receiving the recommended ERT dose of 20 mg/kg/2 weeks
for ≥6 months. Patients <18 years of age who were cross-
reactive immunologic material (CRIM) - negative were
excluded. After reviewing results from this cohort, we
subsequently selected 2 patients in the infantile-onset group
(<18 years of age) for further review to elucidate examples in
which patients who exhibited suboptimal treatment response
with standard ERT may benefit from dose adjustments of
alglucosidase alfa.
2.1. Open-label study design
This open-label, randomized, exploratory, 52-week study
was conducted at 11 centers (9 in the United States, 1 in
Australia, and 1 in Canada) with experience in treating Pompe
disease. The primary objectives were to evaluate the safety and
efficacy of 2 alternate alglucosidase alfa regimens and to
evaluate differences in efficacy between the 2 dosing arms. The
study protocol and informed consent forms were approved by
an Institutional Review Board or Independent Ethics
Committee at each individual study site, and the study complied
with the Declaration of Helsinki. Written informed consent was
provided by all patients or parents/legal guardians.
2.2. Study participants
Eligible patients were clinically diagnosed with Pompe
disease, defined by documented endogenous GAA deficiency in
skin fibroblasts or blood; were compliant in receiving the
standard regimen of alglucosidase alfa (20 mg/kg/2 weeks) for
≥6 months immediately prior to study entry; and experienced
clinical decline or a lack of improvement in ≥1 of the following
parameters compared with their condition prior to beginning
alglucosidase alfa treatment:
• Motor skills
○ For patients ≤2 years of age at study entry, failure to
acquire ≥2 new gross motor milestones (e.g. turning head
side to side [supine], grasping small objects with hands,
transferring objects from hand to hand, holding head
upright with body supported, rolling [supine to prone or
prone to supine], sitting [supported or unsupported],
walking [with support, i.e. cruising or independently],
and walking upstairs [with assistance or independently])
○ For patients previously ambulatory, progression to the
use of an assistive device for ambulation because of
worsening of proximal lower extremity muscle weakness.
• Respiratory
○ New development of respiratory failure requiring the use
of ventilatory assistance (invasive or noninvasive) for ≥4
weeks prior to study enrollment
Among other potential inclusion criteria were cardiac left
ventricular mass (LVM) Z-score of ≥6 or LVM index of ≥150 g/
m2; or for patients >2 years of age at study entry, worsening of
proximal UE muscle weakness through the loss of functional
use of the UEs; or for patients >8 years of age at study entry,
worsening of proximal UE muscle weakness through
longitudinal assessments of manual muscle testing (MMT).
Exclusion criteria were CRIM-negative status and patients
who used any investigational product other than alglucosidase
alfa ≤30 days prior to study enrollment.
2.3. Treatment
Eligible patients were randomized 1:1 to a high-frequency
group (alglucosidase alfa 20 mg/kg/week) or a high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks). Alglucosidase alfa was
supplied by Genzyme, a Sanofi company. Randomization to the
2 treatment groups was stratified by age (<18 years of age and
≥18 years of age), which for the patients enrolled corresponded
with the patients being randomized by phenotype (infantile-
onset and late-onset, respectively). Randomization by age was
done to achieve an even distribution of pediatric and adult
patients in each dosing arm.
2.4. Efficacy assessments
Efficacy was evaluated at scheduled visits and included
gross motor function as measured by the Gross Motor Function
Measure 66 (GMFM-66) [9]; functional status as measured by
the Pompe Pediatric Evaluation of Disability Index (Pompe
PEDI) [10]; proximal and distal muscle strength as measured by
MMT [11] in patients ≥8 years of age; respiratory function as
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measured by ventilator use diary; and health-related quality of
life as measured by the Physical Component Summary (PCS)
score of the Medical Outcomes Study Short Form 36 (MOS
SF-36) [12] in patients ≥14 years of age.
Scoring of the GMFM-66 was completed in a number of
ways because the GMFM-66 has not been validated in Pompe
disease but is considered a measure of functional strength that
can be used to measure change over time. Although originally
designed for use with individuals who have cerebral palsy (CP),
validity in the use of the GMFM has been expanded to
additional diagnoses [13–15], including spinal muscular
atrophy [16], which has clinical characteristics of weakness that
are similar to those of Pompe disease. In fact, at the time of this
study no other assessments had been validated in Pompe
disease, except the Pompe PEDI, which is a measure of
disability and not a measure of performance. Raw scores,
change in raw scores, and percentile change were analyzed to
examine change as thoroughly as possible. Such analyses
allowed consideration of minimal clinically important
differences established for various components of the GMFM.
Calculation of the Gross Motor Ability Estimator (GMAE), the
classic and recommended scoring method for the use of the
GMFM-66, was also performed.
The GMFM-66 total scores percent score was obtained by
adding the percentage scores for GMFM-66 items in each
dimension and dividing the sum by the total number of
dimensions (5 dimensions: Lying and Rolling; Sitting;
Crawling and Kneeling; Standing; and Walking, Running, and
Jumping). The total and individual dimension scores were
summarized over time. Analysis of the GMAE was considered
secondary because the GMAE was based on the normative data
from children with cerebral palsy.
2.5. Safety assessments
Safety evaluations included adverse events (AEs), vital sign
parameters, physical examinations, electrocardiograms
(ECGs), and laboratory measurements (hematology, chemistry,
urinalysis, and antibody monitoring). Additional safety
evaluations included assessments of anti-rhGAA antibody
formation and inhibitory antibody formation (activity and
uptake) in patients with a positive test result for
immunoglobulin G (IgG); immunoglobulin E (IgE), serum
tryptase, complement activation, and skin testing, when
clinically indicated following moderate, severe, or recurrent
infusion-associated reactions (IARs) suggestive of
hypersensitivity; and circulating immune complex detection
when clinically indicated.
2.6. Statistical analysis
Patients were evaluated atWeek 52 for change from baseline
in the parameters in which they demonstrated a lack of
improvement or decline. Descriptive summary statistics were
calculated for continuous variables and shift tables and/or
frequencies for categorical variables. Confidence intervals
(CIs) were used to estimate the mean change in efficacy
parameters within patients irrespective of treatment received.
AEs were summarized by severity, seriousness, relationship to
treatment, and whether they were infusion-related.
3. Results
3.1. Patient demographics, characteristics and disposition
Patient demographics, characteristics, and disposition are
summarized in Table 1. Of the 13 patients enrolled and treated,
11 were Caucasian, 1 was Asian, and 1 was Hispanic. In the
late-onset (≥18 years of age) cohort, 2 patients (both male) were
enrolled in the high-frequency group (alglucosidase alfa 20 mg/
kg/week) and were considerably older than the 2 patients (both
female) in the high-dose group (alglucosidase alfa 40 mg/kg/2
weeks). In the infantile-onset cohort (<18 years of age), 4
patients (2 male, 2 female) were enrolled in the high-frequency
group (alglucosidase alfa 20 mg/kg/week) and 5 patients (4
male, 1 female) in the high-dose group (alglucosidase alfa
40 mg/kg/2 weeks). Patients with infantile-onset disease in the
high-frequency group (alglucosidase alfa 20 mg/kg/week) were
slightly younger than those in the high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks). One patient was
determined to be CRIM-negative after study entry when noted
to have high titers, was discontinued at Week 13, and data from
this patient was not included in the analysis. The patient had
disease-related treatment-emergent AEs (TEAEs) of mild
ptosis and severe right ventricular hypertrophy at the time of
discontinuation. There were no additional patients with high
and sustained titers (≥1:51,200 on more than 2 occasions at or
beyond 6 months on ERT. One patient in the late-onset cohort
discontinued the study after 50 weeks of treatment due to a
treatment-unrelated AE of pneumonia.
3.2. Efficacy
3.2.1. Overall findings
3.2.1.1. Functional change. A total of 11 patients (4 in the
late-onset group and 7 in the infantile-onset group) were
included because they met the criteria for motor decline. Over
the 52-week study period, 6 of the 11 patients (55%; 2 late-
onset [1 high frequency and 1 high dose] and 4 infantile-onset
[1 high frequency and 3 high dose]) displayed motor skill
improvements in raw scores on the GMFM-66 and/or Pompe
PEDI; 3 patients (27%; 1 late-onset [high dose] and 2 infantile-
onset [1 high dose and 1 high frequency]) showed no change
and maintained baseline status; and 1 patient (9%, infantile-
onset [high frequency]) showed continued motor loss. One
patient in the late-onset group experienced a decline in
respiratory status. This patient was invasively vented 13 hours
per day at baseline, required 24-hour ventilation after he was
hospitalized for pneumonia after Week 50 and was not
evaluated at Week 52.
At Week 52, an increasing trend in GMFM-66 total percent
scores was driven by improvements in the sitting dimension
(Table 2). The only difference by treatment group was a trend in
change from baseline to Week 52 in the high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks) with an increase in
GMFM-66 total raw score of 6.7 ± 6.12 (95% CI: 0.2, 13.1)
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compared with the high-frequency group (alglucosidase alfa
20 mg/kg/week) total raw score change of 6.0 ± 8.49 (95% CI:
−7.5, 19.5).
On the Pompe PEDI, trends for change were noted for the
overall population and select subgroups in social function raw
and scaled scores, with and without caregiver assistance; self-
care raw and scaled scores without caregiver assistance; and
self-care raw scores with caregiver assistance (Table 3). No
trends for change in Pompe PEDI Mobility scores were
observed for the overall study population or any of the
subgroups analyzed.
No patient met any of the other potential inclusion criteria,
which included cardiac parameters, worsening of proximal
upper extremity (UE) muscle weakness through the loss of
functional use of the UEs; or for patients >8 years of age at
study entry, worsening of proximal UE weakness through
longitudinal assessments of MMT.
3.2.1.2. Manual muscle testing. For MMT, no trends were
observed for change in upper or lower body muscle strength, or
total muscle strength scores generally, or for the proximal
muscle groups.
3.2.1.3. Respiratory parameters. For respiratory parameters,
no patients were recorded as improved.
3.2.1.4. Health-related quality of life (SF-36 PCS). No trends
were observed for change in either the physical or mental
component summary of the health-related quality of life
assessment.
3.2.2. Late-onset cohort
In the late-onset cohort, all 4 patients were included because
they met the inclusion criteria for motor decline. Most (75%; 3
of 4) patients maintained their baseline GMFM-66 raw scores
or Pompe PEDI status or showed gains at Week 52; 1 patient,
who was hospitalized for pneumonia after Week 50 was not
evaluated and subsequently died. Of the 2 (50%; 2 of 4) patients
who showed improvement, 1 patient in the high-frequency
group (alglucosidase alfa 20 mg/kg/week) acquired the ability
to squat to pick up an item off the floor and the other patient in
the high-dose group (alglucosidase alfa 40 mg/kg/2 weeks)
acquired the ability to walk for 5 blocks, walk on the curb and
on inclines and ramps, ascend an entire flight of stairs with the
use of a handrail, and descend several stairs without a handrail.
For the remaining patient in the late-onset, high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks), no significant change in
motor function was observed.
3.2.3. Infantile-onset cohort
In the infantile-onset cohort, 7 of 9 patients were included
because they met the inclusion criteria for a decline in motor
function and 2 patients were initially included because they met
the criteria for a decline in respiratory function, with one of
these 2 excluded at 13 weeks when CRIM-negative status was
Table 1
Patient demographics and disease history.
Variable Alglucosidase alfa
20 mg/kg/week (n = 6)a
Alglucosidase alfa
40 mg/kg/2 weeks (n = 7)
Total (N = 13)
Male, n 4 4 8
Female, n 2 3 5
Age, years
Mean (SD) 23.3 (27.75) 16.8 (15.56) 19.8 (21.29)
Median (range) 8.8 (1.8–60.1) 14.5 (3.2–40.2) 12.5 (1.8–60.1)
Patients <18 years, n 4 5 9
≤8 3 3 6
9–17 1 2 3
Patients ≥18 years, n 2 2 4
18–44 0 2 2
≥45 2 0 2
Age at first symptom, years
n 5 7 12
Mean (SD) 7.1 (15.36) 8.7 (14.59) 8.0 (14.23)
Median (range) 0.3 (0–34.6) 0.3 (0–32.1) 0.3 (0–34.6)
Age at diagnosis, years
n 6 7 13
Mean (SD) 17.5 (26.25) 9.9 (16.49) 13.4 (20.94)
Median (range) 1.1 (0.1–55.4) 0.4 (0–37.8) 0.5 (0–55.4)
Time on alglucosidase alfa treatment, years
n 6 7 13
Mean (SD) 2.5 (1.27) 2.8 (0.91) 2.7 (1.05)
Median (range) 2.2 (1.2–4.7) 2.9 (1.3–3.7) 2.9 (1.2–4.7)
Duration of disease since symptom onset, years
n 5 7 12
Mean (SD) 9.3 (9.94) 8.0 (5.37) 8.5 (7.22)
Median (range) 4.9 (1.5–25.5) 7.8 (2.9–16.3) 6.4 (1.5–25.5)
SD = standard deviation, CRIM = cross-reactive immunologic material.
a One patient in the 20 mg/kg/week group was determined to be CRIM negative after study entry, was discontinued at week 13, and data were not included in data
analysis.
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identified, and this patient’s data were not included in the
analysis.
Four of the 7 patients (57%) included because of motor
decline displayed improved motor skills on the GMFM-66 or
Pompe PEDI. In the high-frequency group (alglucosidase alfa
20 mg/kg/week), 1 patient acquired the ability to transition from
the sitting to the quadruped position and to maintain the
quadruped position for 10 seconds. In the high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks), 1 patient improved the
ability to run and jump and acquired the ability to maintain a
half-kneel position hands-free; 1 patient acquired the ability to
sit independently for 5 seconds and shift weight to reach objects
in front and behind; and 1 patient acquired the ability to walk
farther distances,walk on uneven terrain,walk backward 10 feet,
pick up an object from the ground, and walk up a full flight of
stairs. For the remaining 3 patients in the infantile-onset group,
2 patients showed no change from baseline (1 in the high-
frequency group [alglucosidase alfa 20 mg/kg/week] and 1 in the
high-dose group [alglucosidase alfa 40 mg/kg/2 weeks]) and 1
patient showed continued motor loss (high-frequency group).
Two patients in the infantile-onset group entered the study
based on the development of respiratory failure. Both patients
were invasively ventilated 24 hours per day at baseline; 1
patient in the high-frequency group (alglucosidase alfa 20 mg/
kg/weeks) who was CRIM-negative discontinued at Week 13,
was not evaluated at Week 52, and was not included in the
data analysis. The other patient, in the high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks), showed no change in
ventilator status at Week 52.
3.3. Safety
All patients in both treatment groups experienced treatment-
emergent AEs (TEAEs), the majority of which (97%; 135
of 139) were assessed as mild or moderate in severity and
unrelated to study drug. The most common TEAEs were upper
respiratory infection, diarrhea, and pyrexia, experienced by 5,
4, and 4 patients, respectively (Table 4). A total of 8 serious
adverse events (SAEs) occurred in 3 of 13 (23%) patients: 1
patient in the infantile-onset, high-frequency group
(alglucosidase alfa 20 mg/kg/week) experienced pneumonia,
and 1 patient in the infantile-onset, high-dose group
(alglucosidase alfa 40 mg/kg/2 weeks) experienced 5 SAEs.
These SAEs included 1 moderate and possibly treatment-
related infusion-associated reaction (IAR) of supraventricular
tachycardia (SVT) and 4 SAEs (SVT, weight decrease, device-
related infection, and dysphagia) considered unrelated to study
treatment. In addition, 1 patient in the late-onset, high-
frequency group died of a cause unrelated to study treatment
(respiratory failure secondary to pneumonia). Additionally, 2 of
13 (15%) patients in the high-dose group (1 in the late-onset
group and 1 in the infantile-onset group) experienced 12
treatment-related IARs; however, only 1 IAR (SVT) was
considered serious. Both patients had a history of IARs during
treatment at the standard dose of 20 mg/kg/2 weeks and
experienced recurrent IARs (erythematous rash in the patient in
the infantile-onset group and headache and dyspnea in the
patient in the late-onset group) at the first 3 infusions of the
current study. None of the IARs were indicative of
Table 2
Gross Motor Function Measure 66 (GMFM-66) percent scores.
Visit Alglucosidase alfa 20 mg/kg/week
(baseline, n = 5; week 52, n = 4;
change, n = 4)
Alglucosidase alfa 40 mg/kg/2 weeks
(baseline, n = 6; week 52, n = 7;
change, n = 6)
Total (baseline, n = 11; week 52,
n = 11; change, n = 10)
Total score
Baseline
Mean (SD) 42.1 (32.91) 47.1 (42.34) 44.8 (36.56)
Median (range) 30.8 (0.0–83.9) 46.8 (5.0–90.0) 30.8 (0.0–90.0)
Week 52
Mean (SD) 40.8 (34.81) 54.6 (42.57) 49.6 (38.73)
Median (range) 39.0 (0.0–85.1) 86.1 (6.7–91.9) 40.5 (0.0–91.9)
Change from baseline
Mean (SD) 4.5 (4.68) 2.1 (3.41) 3.1 (3.92)
Median (range) 4.2 (0.0–9.7) 2.7 (−4.1 to 5.8) 2.7 (−4.1 to 9.7)
95% CI −2.9, 12.0 −1.5, 5.7 0.3, 5.9
Sitting score
Baseline
Mean (SD) 49.3 (39.67) 47.8 (48.29) 48.5 (42.38)
Median (range) 62.2 (0.0–91.1) 45.6 (0.0–100.0) 62.2 (0.0–100.0)
Week 52
Mean (SD) 46.7 (46.44) 62.2 (47.59) 56.6 (45.47)
Median (range) 44.4 (0.0–97.8) 97.8 (0.0–100.0) 73.3 (0.0–100.0)
95% CI
Change from baseline
Mean (SD) 4.4 (5.44) 8.1 (10.20) 6.7 (8.45)
Median (range) 3.3 (0.0–11.1) 3.3 (0.0–22.2) 3.3 (0.0–22.2)
95% CI −4.2, 13.1 −2.6, 18.9 0.6, 12.7
SD = standard deviation, CI = confidence interval.
The GMFM-66 total scores percent score was obtained by adding the percentage scores for each dimension and dividing the sum by the total number of dimensions.
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Table 3
POMPE Pediatric Evaluation of Disability Inventory (POMPE PEDI) component scores.
Score description Visit <18 Years of age (baseline, n = 8;
week 52, n = 8; change, n = 8)
≥18 Years of age (baseline, n = 4;
week 52, n = 3; change, n = 3)
Caregiver assistance social function raw score Baseline
Mean (SD) 15.8 (8.12) 25.0 (0.00)
Median (range) 18.0 (1.0, 25.0) 25.0 (25.0–25.0)
Week 52
Mean (SD) 18.4 (7.31) 25.0 (0.0)
Median (range) 19.0 (2.0–25.0) 25.0 (25.0–25.0)
Change from baseline
Mean (SD) 2.6 (3.16) 0 (0.0)
Median (range) 1.0 (0.0–8.0) 0.0 (0.0–0.0)
95% CI 0.0, 5.3
Caregiver assistance social function scaled score Baseline
Mean (SD) 63.2 (26.43) 100.0 (0.0)
Median (range) 67.7 (11.3–100.0) 100.0 (100.0–100.0)
Week 52
Mean (SD) 71.5 (24.94) 100.0 (0.0)
Median (range) 70.1 (20.4–100.0) 100.0 (100.0–100.0)
Change from baseline
Mean (SD) 8.3 (8.39) 0 (0.0)
Median (range) 5.8 (0.0–21.4) 0.0 (0.0–0.0)
95% CI 1.3, 15.3
Caregiver assistance self-care raw score Baseline
Mean (SD) 10.9 (13.53) 40.0 (0.0)
Median (range) 6.0 (0.0, 38.0) 40.0 (40.0, 40.0)
Week 52
Mean (SD) 14.1 (13.09) 40.0 (0.0)
Median (range) 12.5 (0.0–38.0) 40.0 (40.0–40.0)
Change from baseline
Mean (SD) 3.3 (3.85) 0 (0.0)
Median (range) 2.5 (0.0–11.0) 0.0 (0.0–0.0)
95% CI 0.0, 6.5
Social function raw score Baseline
Mean (SD) 41.8 (20.20) 64.8 (0.50)
Median (range) 49.5 (11.0–65.0) 65.0 (64.0–65.0)
Week 52
Mean (SD) 49.3 (15.38) 65.0 (0.0)
Median (range) 53.0 (18.0–65.0) 65.0 (65.0–65.0)
Change from baseline
Mean (SD) 7.5 (8.68) 0 (0.0)
Median (range) 4.5 (0.0–22.0) 0.0 (0.0–0.0)
95% CI 0.2, 14.8
Score description Visit <18 Years of age (baseline, n = 9;
week 52, n = 8; change, n = 8)
≥18 Years of age (baseline, n = 4;
week 52, n = 3; change, n = 3)
Social function scaled score Baseline
Mean (SD) 59.8 (20.34) 99.1 (1.85)
Median (range) 60.6 (35.1–100.0) 100.0 (96.3–100.0)
Week 52
Mean (SD) 67.0 (19.08) 100.0 (0.00)
Median (range) 63.2 (41.1–100.0) 100.0 (100.0–100.0)
Change from baseline
Mean (SD) 7.1 (7.62) 0 (0.0)
Median (range) 5.1(−1.0 to 20.2) 0.0 (0.0–0.0)
95% CI 0.8, 13.5
Self-care raw score Baseline
Mean (SD) 45.5 (30.42) 118.3 (4.35)
Median (range) 48.5 (7.0–86.0) 118.5 (114.0–122.0)
Week 52
Mean (SD) 56.0 (31.14)
Median (range) 53.0 (12.0–103.0) 120.3 (2.89)
Change from baseline 122.0 (117.0–122.0)
Mean (SD) 10.5 (11.53) 1.0 (1.73)
Median (range) 7.5 (0.0–36.0) 0.0 (0.0–3.0)
95% CI 0.9, 20.1 −3.3, 5.3
Self-care scaled score Baseline
Mean (SD) 49.8 (16.57) 92.9 (8.22)
Median (range) 54.1 (23.1–69.0) 93.2 (85.2–100.0)
Week 52
Mean (SD) 55.8 (14.96) 96.4 (6.18)
Median (range) 56.1 (31.8–76.5) 100.0 (89.3–100.0)
Change from baseline
Mean (SD) 6.0 (6.37) 1.4 (2.37)
Median (range) 3.8 (0.0–20.0) 0.0 (0.0–4.1)
95% CI 0.6, 11.3 −4.5, 7.2
SD = standard deviation, CI = confidence interval.
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anaphylactic/allergic reactions. Eleven of the 13 patients were
IgG seropositive at Day 0 (first study drug infusion) of the
dosing regimen change (10 CRIM-positive, range 400–3200; 1
CRIM-negative, 204,800); 1 patient in the late-onset, high
frequency group was seronegative at Day 0 and remained
seronegative during the study (20 mg/kg/week); and 1 patient in
the infantile-onset, high-dose group was not tested at Day 0 and
remained negative during the study.
The CRIM-negative patient had inhibition of enzyme uptake
and activity at Day 0, exhibited high, sustained anti-rhGAA IgG
antibody titers (204,800 at Day 0, 819,200 at Week 4, and
409,600 at Weeks 8 and 12), experienced 6 TEAEs and was
withdrawn from the study atWeek 13, and data from this patient
was not included in the data analysis. The median peak titer for
the remaining 10 seropositive patients was 1600 (range 800–
3200) and the median last titer was 1200 (range 0–3200). The
median anti-rhGAA IgG antibody titers for patients by
treatment group over time are presented in Fig. 1.
4. Detailed review of 2 patients with infantile-onset
Pompe disease and evidence of response to alternative
alglucosidase alfa dosing
4.1. Common characteristics
Children versus adults were chosen for the case studies to
utilize the Pompe PEDI normative data to describe overall
function and quality of life, including self-care and
socialization. Cases represent patients who had a clear and
well-defined motor decline and different levels of functional
ability. Our goal was to highlight an example of a child
experiencing subtle decline as evident through ambulation and
another child whose highest functional ability was play in an
independent sitting. Overall, we present 2 patients as examples
of when alternative alglucosidase alfa dosing was safe and
beneficial. Both patients were enrolled in this study because
they met the criteria for motor decline. Prior to the study, they
demonstrated an initial beneficial treatment response when
Table 4
Summary of treatment-emergent adverse events occurring in ≥2 patients.
Adverse event Alglucosidase alfa 20 mg/kg/week (n = 6) Alglucosidase alfa 40 mg/kg/2 weeks (n = 7) Total (N = 13)
Patients,
n (%)
Adverse
events, n
Patients,
n (%)
Adverse
events, n
Patients,
n (%)
Adverse
events, n
Any adverse event 6 (100) 72 7 (100) 67 13 (100) 139
Upper respiratory infection 2 (33) 3 3 (43) 4 5 (38) 7
Pyrexia 2 (33) 2 2 (29) 2 4 (31) 4
Diarrhea 2 (33) 2 2 (29) 2 4 (31) 4
Pneumonia 3 (50) 6 0 (0) 0 3 (23) 6
Dermatitis diaper 1 (17) 2 2 (29) 2 3 (23) 4
Gastroenteritis viral 1 (17) 1 1 (14) 1 2 (15) 2
Nasopharyngitis 2 (33) 2 0 (0) 0 2 (15) 2
Otitis media 0 (0) 0 2 (29) 3 2 (15) 3
Viral infection 2 (33) 2 0 (0) 0 2 (15) 3
Abdominal pain upper 2 (33) 2 0 (0) 0 2 (15) 2
Vomiting 2 (33) 2 0 (0) 0 2 (15) 2
Fall 1 (17) 2 1 (14) 2 2 (15) 4
Fig. 1. IgG antibody titers over time by treatment group.
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started on a standard ERT dose of 20 mg/kg/2 weeks. However,
the clinical response reached a plateau and subsequently
declined over time. These patients had low alglucosidase
alfa antibody titers; thus, they had tolerized to ERT. These
patients also received adequate nutrition (with good protein
intake at ~3 g/kg/day) and regular physical and speech
therapy.
4.2. Case 1: patient receiving alglucosidase alfa
20 mg/kg/week
4.2.1. Background
At the time of study initiation, this female patient was age 1
year 10 months and had been diagnosed with Pompe disease at
age 6 months. Her medical history and test results are presented
in Table 5. The patient met the inclusion criterion of failure to
acquire ≥2 new gross motor milestones, and had shown a
decline on the Alberta Infant Motor Scale (AIMS) compared to
age-level peers. She had shown improvements as measured by
the AIMS from 8 months to 20 months but remained below the
5th percentile on the AIMS and was falling further below age-
level peers. On the GMFM-66 and the Pompe PEDI Functional
Skills Mobility domain at baseline, the patient was able to
initiate a head lift but could not sustain an upright head position
in the prone position. She was also able to sit hands-free for 2
seconds and reach out of her base of support to touch a toy at
shoulder level and return to sitting. She was able to move
forward from a prone position <2 feet, and did not have any
controlled transitions in or out of the sitting position. She
was not credited for any items in the crawling, standing, or
walking dimensions of the GMFM-66 test. The patient could
bear minimal weight on her legs to participate in standing
transfers.
4.2.2. Response to higher-frequency dosing (alglucosidase
alfa 20 mg/kg/week)
Results of the patient’s response to alglucosidase alfa
20 mg/kg/week are summarized in Table 5. AEs were mild and
unrelated to alglucosidase alfa. No SAEs occurred.AtWeek 52,
she showed a change rate of +5.41 on the GMAE, which would
be considered a clinically important difference of moderate
effect size [17], and would be considered statistically
significant because of non-overlapping 95% CIs. In sub-
analyses of individual dimensions of the GMFM-66, changes
occurred in Dimension B (Sitting) and Dimension C (Crawling
and Kneeling). On the Pompe PEDI Functional Skills Mobility
domain, both raw and scaled scores increased.
Acquisition of additional motor skill acquisition was
demonstrated on the GMFM-66 and Pompe PEDI, and included
holding her head upright in prone position for 5 seconds,
independent transition from sitting to quadruped positions and
back, and maintenance of quadruped position for 10 seconds.
She was able to take several steps in a walker.
The Pompe PEDI Social Skills domain showed an increase
in both standard and scaled scores. Baseline Social domain
standard score was >2 standard deviations below the mean, and
Table 5
Case 1: Higher-frequency (20 mg/kg/week) of alglucosidase alfa in a patient with infantile-onset Pompe disease.
Demographics
Age 1.8 years
Gender Female
Time of diagnosis 6 months after birth
Medical history Congestive heart failure, left ventricular hypertrophy, failure to thrive, gastroesophageal reflux, hepatomegaly, hypotonia, impaired
swallowing, joint contractures, muscle weakness in the upper and lower extremities, pneumonia, reactive airway disease, and sleep apnea.
She needs an orthopedic device and a feeding tube.
Results
GMFM-66 Baseline (95% CI) Week 52 (95% CI) Change score
GMAE scores 35.26 (32.16–38.05) 40.67 (38.38–42.96) +5.41a
GMFM-66
dimension scores
Dimension A
(lying and rolling)
raw score
Dimension B
(sitting) raw score
Dimension C
(crawling and kneeling)
raw score
Dimension D
(standing)
raw score
Dimension E
(walking, running,and
jumping)
raw score
Raw score
total
Total %
score
Baseline 11 28 0 0 0 39 30.78
Week 52 11 33 10 0 0 54 39.66
Change from baseline 0 5 10 0 0 15 8.88
Pompe PEDI
functional skills
Self-care
domain
standard
score
Mobility
domain
standard
score
Social
function
domain
standard
score
Self-care
domain
scaled
score
Mobility
domain
scaled
score
Social
function
scaled
score
Raw
functional
mobility
score
Baseline 14.2 <10 26.7 35.25 31.28 38.8 22
Week 52 38.97 <10 41.1 55.23 35.57 52.6 30
CI = confidence interval, GMAE = Gross Motor Ability Estimator, PEDI = Pediatric Evaluation of Disability Index.
a Considered a clinically important difference of moderate effect size.
The Gross Motor Function Measure 66 (GMFM-66) total scores percent score was obtained by adding the percentage scores for each dimension and dividing the
sum by the total number of dimensions.
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Week 52 standard score fell within 1 standard deviation of the
mean. Skills acquired during this period included increased
communication with the ability to name things and to use 2
words together. More advanced peer interactions and play skills
emerged, including the ability to manipulate and put toys
together, and she was able to play at home without constant
supervision.
The Pompe PEDI Self-Care domain scaled and standard
scores both increased, and significant improvements in feeding
were documented. At baseline, she was not taking any food or
drinks orally.AtWeek 52, she was drinking liquids from a sippy
cup, using a straw, and eating all textures of food except hard
food – reflecting improved oral motor function, including
strength needed for chewing and swallowing. Her level of
participation increased in all activities of daily living, including
dressing; bathing; and care of hair, teeth, and nose. Acquisition
of new skills included the ability to scribble with a marker and
to access a computer icon using a mouse, potentially reflecting
increased distal strength.
4.3. Case 2: patient receiving alglucosidase alfa 40 mg/kg/2
weeks
4.3.1. Background
This male patient was diagnosed with Pompe disease at age
3 months and was enrolled in this study at age 3 years 2 months.
His medical history and test results are presented in Table 6.
The patient met the inclusion criterion of use of an assistive
device for ambulation due to worsening of proximal lower
extremity muscle weakness. He had shown a decreased rate of
change on the GMAE prior to the study compared with
previously higher rates of change (+20.66 in first year on ERT
with alglucosidase alfa and +13.65 in the first half of the second
year on ERT with alglucosidase alfa), with a decline in status
over the subsequent 4 months in the second year (change rate of
−1), and had begun to show increased falls in all settings. He
initially achieved walking with a walker and began walking
independently without a walker at 2 years 2 months, but began
to show increased falls at 2 years 10 months. In addition, he
showed deteriorating gait kinematics, including decreased
ankle dorsiflexion, increased foot drop, and decreased hip
extension (with increased use of compensatory patterns,
including steppage gait), and increasing lumbar lordosis. On
baseline GMFM-66 and PEDI Functional Skill Mobility
domain testing, he was able to walk independently but was only
able to climb stairs if holding onto 2 railings, 1 on each side,
could not pick up an object off the floor without hand support,
and could only stand on 1 foot if holding on with 2 hands.
4.3.2. Response to higher dosing (alglucosidase alfa
40 mg/kg/2 weeks)
Results of the patient’s response to alglucosidase alfa
40 mg/kg/2 weeks are presented in Table 6. AEs were mild and
unrelated to alglucosidase alfa. No SAEs occurred.AtWeek 52,
there was a change score of +7.89 on the GMAE, which would
Table 6
Case 2: higher dose of alglucosidase alfa (40 mg/kg/2 weeks) in a patient with infantile-onset Pompe disease.
Demographics
Age 3.2 years
Gender Male
Time of diagnosis 3 months after birth
Medical history Cardiac arrhythmia, left ventricular hypertrophy, chronic otitis media, failure to thrive, feeding difficulties, gastroesophageal reflux,
hypotonia, joint contractures, delayed and regression of motor milestones, pneumonia, and reactive airway disease. He needs a feeding tube
for nutritional support, although he can eat by mouth.
Results
GMFM-66 Baseline (95% CI) Week 52 (95% CI) Change Score
GMAE scores 58.80 (56.39–61.21) 66.69 (63.81–69.57) +7.89a
GMFM-66
dimension scores
Dimension A
(lying and rolling)
raw score
Dimension B
(sitting)
raw score
Dimension C
(crawling and kneeling)
raw Score
Dimension D
(standing)
raw score (%)
Dimension E
(walking,
running, and jumping)
raw score (%)
Raw
score
total
Total % score
Baseline 12 35 30 26 (66%) 41(56.94%) 144 80.28
Week 52 12 45 27 31 (79%) 44 (61.11%) 159 86.12
Change from
baseline
0 +10 −3 +5 (+12.82%)a +3 (+4.17%)a 15 5.84
Pompe PEDI
functional
skills
Self-care
domain
standard score
Mobility domain
standard score
Social function
domain
standard score
Self-care
domain
scaled Score
Mobility
domain
scaled score
Social
function
scaled score
Raw functional
mobility
score
Baseline 27.06 18.42 36.8 52.04 51.57 49.7 75
Week 52 12.42 13.95 37.9 56.08 57.27 62.3 94
CI = confidence interval, GMAE = Gross Motor Ability Estimator, PEDI = Pediatric Evaluation of Disability Index.
a Considered a clinically important difference of moderate effect size.
The Gross Motor Function Measure 66 (GMFM-66) total scores percent score was obtained by adding the percentage scores for each dimension and dividing the
sum by the total number of dimensions.
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be considered a clinically important difference of moderate
effect size [17], and would be considered statistically
significant because of non-overlapping 95% CIs. In sub-
analyses of change on individual dimensions of the GMFM-66,
the patient demonstrated improvement in Dimension B
(Sitting), Dimension D (Standing), and Dimension E (Walking,
Running, and Jumping). In Dimensions D and E, for which
individual GMFM Dimension change scores and minimal
clinically important differences (MCIDs) are available, he
showed a change score of +12.82 and +4.17, respectively, both
of which would be considered clinically important differences
of moderate effect size [18]. He could walk farther and on
uneven terrain, stand on 1 foot while holding on with only 1
hand, pick up an object from the ground and return to standing
position without hand support, and walk up stairs holding onto
only 1 railing, reflecting improved functional lower extremity
strength. His respiratory status remained unchanged
(ventilator-free).
The patient’s Pompe PEDI Social Skills domain scaled score
increased. He acquired increased communication (put 4 to 5
words together), more complex fine-motor skills, and was able
to play at home and in the community without constant
supervision.
The Pompe PEDI Self-Care Skills domain scaled score
increased, demonstrating increased independence, although a
decrease in the standard score showed that his rate of skill
acquisition was not the same as his normative peer sample. New
skill items present at 52 weeks included drinking from a straw,
managing a water faucet independently, and increased
independence in brushing his teeth and wiping his nose.
5. Discussion
Before the approval of alglucosidase alfa for the treatment of
Pompe disease in 2006, the prognosis for affected infants was
poor and life expectancy was short. Since then, the natural
history of infantile Pompe disease on ERT has changed
significantly, in particular with regard to survival. The clinical
experience among infantile survivors has shown residual
weakness in some in spite of overall benefit and increased
survival [7,8], with some patients eventually starting to exhibit
progression of weakness and decline in function, prompting
questions about long-term pathophysiology and dosing
optimization. Factors such as ongoing glycogen storage,
autophagic cellular abnormalities, and mitochondrial
dysfunction may promote ongoing muscle damage or
compromise effective enzyme delivery [19], perhaps
contributing to a phenotype characterized by progression of
weakness, and functional decline in some patients over time
despite standard initial treatment [7,8]. Additionally, the initial
dosing may not sufficiently keep up with increasing muscle
mass and metabolic demands associated with physical
maturation. Other potential factors include mounting an
immune response to ERT, poor nutrition, a lack of adequate
therapies (occupational, physical, and speech therapy), and not
receiving a multidisciplinary approach to care. Increased
dosage has been shown to improve the clinical outcome in
ptosis and may be needed in additional situations [20]. The
current study evaluated the safety and exploratory efficacy of
alternative, more intensive alglucosidase alfa regimens (high
frequency at 20 mg/kg/week or high dose at 40 mg/kg/2 weeks)
in initially responsive patients with declining function during
standard ERT with alglucosidase alfa at 20 mg/kg/2 weeks.
No systematic studies have examined the use of higher doses
of ERT in patients with Pompe disease experiencing motor
deterioration with standard dosing. In a case report, a higher
ERT dose at 40 mg/kg/2 weeks yielded well-tolerated motor
improvement and partial reversal of ptosis after 6 months in a
13-year-old patient who experienced diminished muscle
strength after standard ERT with alglucosidase alfa for 2 years
[20]. None of the patients in the current study had high and
sustained anti-rhGAA titers (except one individual whose
CRIM-negative status was diagnosed after study inclusion and
was withdrawn from the study at week 13 with data not
included in data analysis). Given these limitations, it is still
important to recognize that this is the largest study looking at
dose effect in a group of individuals with Pompe disease
showing a clinical decline over time on ERT with alglucosidase
alfa dosing based on the package insert [4]. Although
improvement in motor function suggests a benefit of increased
dose, stabilization can also suggest an improvement in patients
who were in decline because continued decline could have been
expected if treatment were continued with the standard dose of
alglucosidase alfa at 20 mg/kg/2 weeks. In the current study,
GMFM-66 total percent scores demonstrated an overall trend
for motor improvement from baseline after 52 weeks of more
intensive ERT with alglucosidase alfa. In addition, 6 of 11
(55%) patients who entered the study because of a decline or
clinical plateau in motor skills showed functional improvement
with increased dose of ERT. No trends for differences in
efficacy emerged between the 2 dosing arms, although this may
be attributed to the small sample size (N = 13), heterogeneity
in age distribution (range, 1.8–60.1 years), and functional
presentation (infantile-onset group and late-onset group) at
baseline. Additionally, patients were enrolled based on either
motor decline (n = 11) or respiratory decline (n = 2). The large
variability in the level of disability and functional status in
this study prevented a meaningful and conclusive analysis of
mean functional change from baseline and between treatment
arms.
The detailed review of 2 infantile patients may provide
more informative clinical insights into the effects of higher or
more frequent alglucosidase alfa dosing in selected patients
who experience motor decline while receiving standard ERT
with alglucosidase alfa. After the 52-week study period, these
2 patients demonstrated improvement in motor skills, with
gains on the GMFM-66 raw scores and Pompe PEDI
Functional Mobility, Self-Care, and Social Function domains.
These data suggest that the improvements in functional
mobility and quality of movement observed during treatment
with higher doses of ERT with alglucosidase alfa may provide
a basis for meaningful enhancements in self-care and
socialization skills. Moreover, the improvements in fine motor
skills seen in these patients may translate into increased levels
of functional independence in the home and school
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environments, with less reliance on adult caregivers for daily
home and academic needs.
The overall safety profile in this study is consistent with the
overall safety experience with alglucosidase alfa. Most TEAEs
were of mild or moderate severity and unrelated to the use of
alglucosidase alfa. No new safety concerns emerged for either
dose regimen. None of the patients, other than the one CRIM-
negative patient, had an increase in titers since the increase in
dose on ERT; in fact, all had low antibody titers (IgG titers
≤3200 at Day 0, peak, and last titers).
This study was limited by the small sample size, although
small clinical studies are not uncommon in the investigation of
rare diseases [21]. Also, the study did not include direct
assessment of muscle pathology which may or may not have
identified potential causes of resistance to ERT. However, this is
the largest study of increased dosing in individuals on ERT with
alglucosidase alfa who had been showing clinical decline. The
interpretation of the study results was also limited by the
heterogeneity of the sample and the absence of a control group
that continued to receive ERT with alglucosidase alfa at doses
based on the package insert.
The results of this study, although statistically inconclusive,
and the case studies presented, suggest that an increase in ERT
alglucosidase alfa dose may be beneficial in patients with
Pompe disease who are experiencing plateau or decline in
motor function over time while receiving a standard regimen.
The clinical improvements or stabilization observed in
individual patients can be considered improvement in patients
who are otherwise in clinical decline. Thinking about dose-
adjustment experiences in the setting of clinical plateau and
decline is important because rapid progression of the disease is
well-documented. However, controlled studies in a more
homogeneous patient cohort – i.e. in patients with infantile-
onset disease experiencing motor decline – are clearly needed
to elucidate the benefits and risks of this alternative regimen
because the current recommend dose of ERT is alglucosidase
alfa 20 mg/kg/2 weeks [4] and is insufficient in many cases [3].
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